Parallel Artificial Membrane Permeability Assay (PAMPA)
- Service Details
- Features
- Study Example
- FAQ
Membrane permeability and intestinal absorption are important properties to understand early in drug development to minimize late-stage attrition. Our PAMPA service offers a rapid, low-cost, high throughput in vitro model to assess passive permeability before moving into more sophisticated cell-based or in vivo models.
Using a lipid-infused artificial membrane system, PAMPA enables quantitative assessment of compound transport from a donor to an acceptor compartment, offering a reliable early ADME screening tool for compound prioritization. Since there are no living cells involved in the PAMPA assay, you get clean, reproducible data you can use to make go/no-go decisions about your compounds during hit-to-lead and lead optimization.
When Should You Choose PAMPA?
PAMPA is particularly well suited for projects that require rapid decision-making and efficient resource allocation, including:
- Early-stage screening of large compound libraries
- Prioritization of hits before investing in Caco-2 or MDCK assays
- Evaluation of passive transcellular permeability without transporter interference
- Initial assessment of oral absorption potential or blood–brain barrier (BBB) penetration
For compounds where active transport or efflux mechanisms are expected to play a major role, PAMPA is best used in combination with cell-based permeability models.
Our PAMPA Methods
We offer specialized PAMPA models designed to simulate key biological barriers relevant to drug absorption and distribution:
GIT-PAMPA: It is used to evaluate the permeability of drugs in the gastrointestinal tract and simulate the intestinal environment.
BBB-PAMPA: This method assesses the permeability of compounds across the blood-brain barrier.
Skin-PAMPA: Specializes in evaluating the permeation of compounds through the skin barrier.
Workflow

| PAMPA | Details |
| Test Article Concentration | 10 μM |
| Number of Replicates | 3 |
| Membrane Composition | Tri-layers of Phospholipids (Pre-coated) |
| Incubation Time | 4 hours |
| Test Article Requirements | 50 µL of 10 mM DMSO solution Brutto formulas are required. |
| Analysis Method | LC-MS/MS quantification |
| Data Delivery | Permeability (x10-6 cm/s). Full study report is provided. |
| Positive Control | Propranolol (high permeability) |
| Negative Control | Atenolol (low permeability) |
Why Work with Us?
Proven Expertise in Permeability Testing
Our scientists bring extensive experience in in vitro ADME screening, ensuring accurate data generation and interpretation.
Reliable and Decision-Ready Data
Standardized protocols and strict quality controls deliver reproducible results suitable for internal decision-making pipelines.
Flexible and Customizable Study Design
Assay conditions, analytical methods, and reporting formats can be tailored to meet specific project needs.
Technical Consultation Support
Our experts help you determine whether PAMPA is the right model for your compound and how to integrate results with downstream assays.
Study Example
A high throughput, high content screen for non-toxic small molecules that reduce levels of the nuclear lamina protein, Lamin B1
Background
Lamin B1 (LMNB1) overexpression causes Autosomal Dominant Leukodystrophy (ADLD) and is linked to poor cancer outcomes. This study performed a high-throughput/high-content screen of ~97,000 small molecules using an inducible mouse fibroblast model of LMNB1 overexpression. Two non-toxic compounds, CID 662896 and CID 5308648, reduced LMNB1 dose-dependently and corrected nuclear abnormalities. CID 662896 also lowered LMNB1 in ADLD patient fibroblasts, showed favorable drug-like properties, and crossed the blood-brain barrier in mice, highlighting its therapeutic potential for ADLD.
Key Findings
Approximately 97,000 compounds were screened using TRE-FLAG-LMNB1 mouse embryonic fibroblasts. After stringent filtering for LMNB1 reduction, LMNA/C selectivity, and cell viability, two small molecules, CID 662896 and CID 5308648, were confirmed to reduce LMNB1 in a dose-dependent manner with mean EC50 values of 8.6 and 8.7 µM, respectively, without toxicity. Both compounds corrected LMNB1-induced nuclear abnormalities, but only CID 662896 significantly reduced endogenous LMNB1 in ADLD patient fibroblasts. CID 662896 had favorable drug-like physicochemical properties, no PAINS or toxicity flags, and was predicted to cross the BBB. PAMPA assays and mouse pharmacokinetic studies confirmed BBB penetration, with brain-to-plasma ratios around 0.108–0.138. Preliminary SAR indicated the 4H,5H,6H,7H-[1,2,4]triazolo[1,5-a]pyrimidine core is essential. The study demonstrates a successful high-content screening strategy and identifies CID 662896 as a promising non-toxic LMNB1-reducing lead for ADLD.
Contribution
Creative Bioarray performed the parallel artificial membrane permeability assay (PAMPA) to assess blood-brain barrier permeability of CID 662896 and CID 5308648. They used artificial brain lipid-coated membranes, LC-MS/MS quantification, and propranolol/atenolol controls, providing key data showing both compounds cross the BBB.
Selective histone deacetylase inhibition as a therapeutically relevant strategy in H3K27M-glioma
Background
This study defines isoform-specific histone deacetylase (HDAC) dependencies in H3K27M-mutant diffuse midline glioma (DMG). Combining CRISPR/Cas9 screening with pharmacological profiling of patient-derived DMG cell lines, the authors identify Class I HDACs, especially HDAC2, as selective essential dependencies. They characterize Compound 26, a CNS-penetrant HDAC1/2-selective inhibitor that restores physiologic pontine histone patterns, reorganizes chromatin, triggers G1 cell cycle arrest, and suppresses tumor growth and prolongs survival in orthotopic xenograft models.
Key Findings
HDAC2 is highly expressed in primary DMG and enriched in cycling, stem-like tumor cells, and emerges as a selective genetic dependency in CRISPR/Cas9 screens across DMG lines and the DepMap/CCMA datasets, whereas Class II/III isoforms are dispensable. Chemical profiling showed that only Class I HDAC inhibition (panobinostat, romidepsin, entinostat, Merck 60) robustly reduced DMG viability. Compound 26 was identified as a potent HDAC1/2-selective inhibitor (IC50 27 nM/170 nM) with favorable physicochemical properties, high BBB-PAMPA permeability, and ~15-fold higher brain than plasma concentrations in mice. Compound 26 induced G1 arrest with minimal apoptosis or DNA damage, drove transcriptional reprogramming with upregulation of p16/p21 and loss of the DMG cycling program, and globally increased H3K27ac and H3K27me3, reordering chromatin loops and TAD boundaries including at CDKN2A enhancers. In two orthotopic PDX models, oral Compound 26 was well tolerated, reduced tumor burden and extended survival.
Contribution
Creative Bioarray performed the blood-brain barrier parallel artificial membrane permeability assay (BBB-PAMPA) to assess passive permeability of Compound 26 and comparator HDAC inhibitors. These data provided key in vitro evidence of predicted CNS penetration that supported selection of Compound 26 for downstream pharmacokinetic, pharmacodynamic and in vivo efficacy studies.
Developmental, Behavioral and Transcriptomic Changes in Zebrafish Embryos after Smoke Dye Exposure
Background
This study assessed developmental, behavioral, and transcriptomic effects of four smoke dyes—Disperse Blue 14, Disperse Red 9, Solvent Red 169, and Solvent Yellow 33—on zebrafish embryos. Embryos were exposed from 6 to 120 hpf and evaluated for mortality, morphology, photomotor behavior, and gene expression at 48 hpf. Blood–brain barrier permeability was also tested. Solvent Yellow 33 and Disperse Blue 14 impaired development and behavior; Disperse Red 9 affected behavior and development; Solvent Red 169 showed no effects. Transcriptomics implicated neurodevelopment, folate, and retinol metabolism. The findings suggest smoke dyes may pose developmental and neurotoxic hazards.
Key Findings
Solvent Yellow 33 and Disperse Blue 14 impaired development and behavior at all tested concentrations, while Disperse Red 9 impaired behavior at all concentrations and development except at 10 µM. Solvent Red 169 caused no mortality or morphological effects and only minor behavioral and transcriptional changes. Mortality occurred only with Disperse Blue 14 at 261.5 and 314 µM. Disperse Blue 14 caused yolk sac edema and dark-phase hypoactivity; Solvent Yellow 33 caused yolk sac and pericardial edema, bent axis, pectoral fin abnormalities, and dark-phase hypoactivity. Disperse Red 9 caused morphological abnormalities at ≥25 µM and altered light/dark locomotor activity. Transcriptomic analysis at 48 hpf revealed differentially expressed genes related to neurodevelopment, DNA damage, oxidative stress, folate synthesis, and retinol metabolism. Blood–brain barrier permeability assays showed Disperse Red 9, Disperse Blue 14, and Solvent Yellow 33 are highly permeable, suggesting potential to reach the brain. Overall, smoke dyes have high potential for developmental changes and neurotoxicity.
Contribution
Creative Bioarray performed the blood–brain barrier parallel artificial membrane permeability assay (BBB-PAMPA) to assess whether the smoke dyes cross the blood–brain barrier. This contribution provided key in vitro permeability data, showing high permeability for Disperse Red 9, Disperse Blue 14, and Solvent Yellow 33, and supporting the neurotoxicity assessment.
FAQ
Q1: How should PAMPA data be interpreted?
PAMPA evaluates drug permeability through artificial membranes by analyzing passive diffusion which serves as the main route through which drugs are absorbed in the gastrointestinal tract as well as across the blood-brain barrier and cellular membranes. The classification of compounds into either low permeability (Pe < 1.5 x 10-6 cm/s) or high permeability (Pe > 1.5 x 10-6 cm/s) assists researchers in selecting potential candidates for additional development processes.
Q2: Is PAMPA applicable to all types of compounds?
PAMPA provides excellent evaluation of passive transport attributes but lacks the ability to measure active transport processes. To obtain complete absorption data for compounds, researchers should combine PAMPA testing with cell-based methods such as Caco-2 assays.
Q3: What are the differences between PAMPA and other permeability testing methods?
The primary distinctions between PAMPA and permeability testing methods such as Caco-2 and MDCK cell models lie in the type of model they use and their operational complexity.
- Cell-free model: PAMPA employs synthetic membranes in its cell-free design while Caco-2 and MDCK models operate using live cells. The use of PAMPA removes any influence of cellular differences and metabolic processes when measuring permeability.
- Simplified operation: PAMPA provides a simpler operation compared to cell-based models because it eliminates the need for cell culture which streamlines experimentation and decreases time requirements.
- High-throughput screening: PAMPA's simplified operational process makes it exceptionally suitable for high-throughput screening which allows rapid permeability evaluation of compounds during early drug development phases.
- Cost-effectiveness: PAMPA provides a more cost-effective permeability testing option than cell models such as Caco-2 because it eliminates the need for cell culture.
- Data comparability: Caco-2 and MDCK models potentially deliver data that better represents physiological conditions for complex transmembrane permeability characterization because they reproduce biological barriers more accurately than PAMPA which provides useful permeability data.
Quotation and ordering
If you have further inquiries or need additional assistance, please contact our expert team.
Reference
- Ponmozhi J, Dhinakaran S, et al. Development of Skin-On-A-Chip Platforms for Different Utilizations: Factors to Be Considered. Micromachines. 2021; 12(3):294.
Explore Other Options